目的 探讨薄芝糖肽注射液联合吡柔比星和多西他赛治疗乳腺癌的临床疗效。方法 选取天津市第五中心医院2013年12月—2016年12月收治的乳腺癌患者101例，随机分成对照组（50例）和治疗组（51例）。对照组患者静脉滴注注射用盐酸吡柔比星，50 mg/m²加入5%葡萄糖注射液250 mL，同时静脉滴注多西他赛注射液，75 mg/m²加入5%葡萄糖注射液250 mL，1次/3周，连续治疗12周。治疗组患者在对照组的基础上静脉滴注薄芝糖肽注射液，8 mL加入5%葡萄糖注射液250 mL，连续治疗1周，然后停药2周为1个周期，连续治疗4个周期。观察两组患者临床疗效，比较治疗前后两组患者肿瘤细胞凋亡指数、新生血管指标、情绪状态和生活质量评分以及不良反应情况。结果 治疗后，对照组客观缓解率（ORR）和疾病控制率（CBR）分别为46.00%、78.00%，均分别明显低于治疗组的68.63%、94.12%，两组比较差异均具有统计学意义（P<0.05）。治疗后，两组患者肿瘤细胞凋亡指数显著升高，血管内皮生长因子A（VEGFA）和VEGFB均显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者上述指标改善水平明显优于对照组（P<0.05）。治疗后，两组患者焦虑自评量表（SAS）和抑郁自评量表（SDS）评分均明显降低，卡氏评分（KPS）明显升高，同组比较差异具有统计学意义（P<0.05）；且治疗组上述评分显著优于对照组（P<0.05）。治疗期间，对照组患者不良反应发生率为34.00%，显著高于治疗组患者的13.73%，两组比较差异具有统计学意义（P<0.05）。结论 薄芝糖肽注射液联合吡柔比星和多西他赛治疗乳腺癌患者疗效显著，同时还能改善患者的情绪状态与生存质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Bozhitang Injection combined with pirarubicin and docetaxel in treatment of breast cancer. Methods Patients (101 cases) with breast cancer in Tianjin Fifth Central Hospital from December 2013 to December 2016 were randomly divided into control (50 cases) and treatment (51 cases) groups. Patients in the control group were iv administered with Pirarubicin Hydrochloride for injection, 50 mg/m² added into 5% Glucose Injection 250 mL, at the same time, they were iv administered with Docetaxel Injection, 75 mg/m² added into 5% Glucose Injection 250 mL, once every 3 weeks. Patients in the treatment group were iv administered with Bozhitang Injection on the basis of the control group, 8 mL added into 5% Glucose Injection 250 mL, 1 weeks of continuous treatment and withdrawal for 2 weeks was one course of treatment, and they were treated for 4 coures. After treatment, the clinical efficacy was evaluated, and the apoptosis index of tumor cells, angiogenesis index, emotional status and quality of life scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, ORR and CBR in the control group were 46.00% and 78.00%, which were significantly lower than 68.63% and 94.12% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the apoptosis index of tumor cells in two groups was significantly increased, VEGFA and VEGFB levels were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the improvement level of these indicators in the treatment group was significantly better than that the control group (P < 0.05). After treatment, the SAS and SDS scores in two groups were significantly decreased, but KPS scores were significantly increased, and there were differences in the same group (P < 0.05). And these scores in the treatment group were significantly better than that the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the control was 34.00%, which was significantly higher than 13.73% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Bozhitang Injection combined with pirarubicin and docetaxel has significant effect in treatment of breast cancer, and also can improve the emotional state and quality of life, which has a certain clinical application value.